Cargando…
Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients
BACKGROUND: Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation index (TMI) model for screening responders (from non-responders) among NSCLC pat...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336041/ https://www.ncbi.nlm.nih.gov/pubmed/35906676 http://dx.doi.org/10.1186/s40364-022-00400-5 |
_version_ | 1784759460029267968 |
---|---|
author | Lu, Jun Wu, Jun Lou, Yuqing Shi, Qin Xu, Jun Zhang, Lele Nie, Wei Qian, Jie Wang, Yanan Zhang, Yanwei Jiao, Jing Zhang, Xueyan Zhang, Wei Wang, Huimin Chu, Tianqing Zhong, Hua Han, Baohui |
author_facet | Lu, Jun Wu, Jun Lou, Yuqing Shi, Qin Xu, Jun Zhang, Lele Nie, Wei Qian, Jie Wang, Yanan Zhang, Yanwei Jiao, Jing Zhang, Xueyan Zhang, Wei Wang, Huimin Chu, Tianqing Zhong, Hua Han, Baohui |
author_sort | Lu, Jun |
collection | PubMed |
description | BACKGROUND: Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation index (TMI) model for screening responders (from non-responders) among NSCLC patients who received monotherapy with docetaxel or atezolizumab. METHODS: We performed a retrospective analysis of the POPLAR (NCT01903993) and OAK (NCT02008227) trials. We identified three biomarkers, blood tumour mutation burden (bTMB), sensitive blood tumour mutation burden (sbTMB) and unfavourable mutation score (UMS), of the ctDNA profiles. After integrating the advantages and disadvantages of the three independent biomarkers, we developed the TMI model and identified NSCLC patients who may benefit from monotherapy with docetaxel or atezolizumab in terms of overall survival (OS). RESULTS: The TMI model as a stratified biomarker for docetaxel responders provided a median OS duration of 5.55 months longer than non-responders in the OAK cohort, with a significantly decreased hazard ratio (HR). Moreover, atezolizumab responders had a 10.21-month OS advantage over atezolizumab non-responders in the OAK cohort via TMI stratification, and the HR was also decreased significantly. The TMI demonstrated effectiveness for stratifying responders in the POPLAR cohort. Importantly, we found that the TMI model could screen additional responders upon combining the cohorts from the POPLAR and OAK trials after adjustment. CONCLUSION: In the present study, we provide a novel TMI model for screening responders (from non-responders) among NSCLC patients who received the 2nd-line monotherapy with docetaxel or atezolizumab. We believe that the biomarker TMI will potentially be effective for the clinical treatment of NSCLC in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-022-00400-5. |
format | Online Article Text |
id | pubmed-9336041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93360412022-07-30 Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients Lu, Jun Wu, Jun Lou, Yuqing Shi, Qin Xu, Jun Zhang, Lele Nie, Wei Qian, Jie Wang, Yanan Zhang, Yanwei Jiao, Jing Zhang, Xueyan Zhang, Wei Wang, Huimin Chu, Tianqing Zhong, Hua Han, Baohui Biomark Res Research BACKGROUND: Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation index (TMI) model for screening responders (from non-responders) among NSCLC patients who received monotherapy with docetaxel or atezolizumab. METHODS: We performed a retrospective analysis of the POPLAR (NCT01903993) and OAK (NCT02008227) trials. We identified three biomarkers, blood tumour mutation burden (bTMB), sensitive blood tumour mutation burden (sbTMB) and unfavourable mutation score (UMS), of the ctDNA profiles. After integrating the advantages and disadvantages of the three independent biomarkers, we developed the TMI model and identified NSCLC patients who may benefit from monotherapy with docetaxel or atezolizumab in terms of overall survival (OS). RESULTS: The TMI model as a stratified biomarker for docetaxel responders provided a median OS duration of 5.55 months longer than non-responders in the OAK cohort, with a significantly decreased hazard ratio (HR). Moreover, atezolizumab responders had a 10.21-month OS advantage over atezolizumab non-responders in the OAK cohort via TMI stratification, and the HR was also decreased significantly. The TMI demonstrated effectiveness for stratifying responders in the POPLAR cohort. Importantly, we found that the TMI model could screen additional responders upon combining the cohorts from the POPLAR and OAK trials after adjustment. CONCLUSION: In the present study, we provide a novel TMI model for screening responders (from non-responders) among NSCLC patients who received the 2nd-line monotherapy with docetaxel or atezolizumab. We believe that the biomarker TMI will potentially be effective for the clinical treatment of NSCLC in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-022-00400-5. BioMed Central 2022-07-29 /pmc/articles/PMC9336041/ /pubmed/35906676 http://dx.doi.org/10.1186/s40364-022-00400-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lu, Jun Wu, Jun Lou, Yuqing Shi, Qin Xu, Jun Zhang, Lele Nie, Wei Qian, Jie Wang, Yanan Zhang, Yanwei Jiao, Jing Zhang, Xueyan Zhang, Wei Wang, Huimin Chu, Tianqing Zhong, Hua Han, Baohui Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients |
title | Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients |
title_full | Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients |
title_fullStr | Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients |
title_full_unstemmed | Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients |
title_short | Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients |
title_sort | blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336041/ https://www.ncbi.nlm.nih.gov/pubmed/35906676 http://dx.doi.org/10.1186/s40364-022-00400-5 |
work_keys_str_mv | AT lujun bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT wujun bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT louyuqing bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT shiqin bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT xujun bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT zhanglele bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT niewei bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT qianjie bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT wangyanan bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT zhangyanwei bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT jiaojing bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT zhangxueyan bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT zhangwei bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT wanghuimin bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT chutianqing bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT zhonghua bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients AT hanbaohui bloodbasedtumourmutationindexactasprognosticpredictorforimmunotherapyandchemotherapyinnonsmallcelllungcancerpatients |